Caligan Partners’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.6M Buy
+1,163,010
New +$8.27M 0.65% 22

Other funds holding EPRX

Caligan Partners's EPRX Position: Q3 2026 in Review

Caligan Partners opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q3 2026: 1,163,010 shares worth $10.6M. The stake represents 0.65% of the portfolio and ranks #22 among its holdings.

70 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.

  • Caligan Partners held 1,163,010 shares of Eupraxia Pharmaceuticals worth $10.6M as of Q3 2026.
  • Eupraxia Pharmaceuticals was a new Caligan Partners position in Q3 2026.
  • Eupraxia Pharmaceuticals made up 0.65% of Caligan Partners's portfolio in Q3 2026, its #22 holding.
  • 70 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.

Based on Caligan Partners's 13F filing for Q3 2026, filed 16 Nov 2026.